ArticleFrontiers in bioinformatics2025
CIT kinase phosphorylation as significant regulatory node for cellular checkpoints.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of cellular phosphoproteome datasets exploring phospho-signaling associated with the RNA-binding protein RAVER1.Scientific reports · 2026Pooled it
- Deciphering Site-Specific Regulatory Networks of the Kinesin Protein KIF21A Through Integrative Phosphoproteomic Analysis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Citron Rho-interacting serine/threonine kinase (CIT) is a major cytosolic protein kinase essential for midbody organisation, abscission, and cytokinesis. Dysregulation and mutations in CIT are associated with multiple cancers and neurodevelopmental disorders, including microcephaly. Although global phosphoproteomic studies have identified more than 50 phosphosites in CIT, their functional relevance and the kinases regulating them remain largely unexplored. Methods: To systematically investigate the phosphoregulation of CIT, we curated and integrated global phosphoproteomic datasets, along with their associated experimental conditions, to comprehensively catalogue phosphorylation events reported for CIT. To assess the functional significance of CIT, we examined proteins that were differentially co-regulated with its predominant phosphosite. Results: Serine 440 (S440), located outside the kinase domain (representing over 55% of CIT-associated phospho-signalling events across 100 experimental conditions, including Enterovirus A71 infection, metformin, and interleukin-33), was identified as its predominant phosphosite. Motif analysis revealed the presence of a D(S/T)P/P(S/T)D motif recognised by the CIT kinase domain, suggesting S440 as a predicted autophosphorylation site. Co-phosphoregulation analysis identified 136 interacting proteins and 82 predicted substrates that were positively co-regulated with CIT_S440. The resulting phospho-regulatory network comprised essential cell cycle and DNA repair regulators, including MDC1 and TRIP12. Significantly, over 120 co-regulated phosphosites were functionally linked to DNA repair and cell cycle regulation. Aberrant phosphorylation of CIT_S440 observed across cancers of the breast, colon, and bladder suggests CIT_S440 as a potential onco-phosphosite critically involved in cellular checkpoint signalling. Discussion: These findings suggest that CIT_S440 functions as a promising therapeutic target, and the phosphosite-centric regulatory network derived in this study could serve as a platform to evaluate its phosphosite-specific therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.